「decision」の検索結果

Cross-method decision tree for calling hits in pooled CRISPR screens. Catalogs statistical models (MAGeCK RRA, MAGeCK MLE, BAGEL2, drugZ, JACKS, Chronos, CERES), experimental designs each is built for, failure modes outside design domain, reconciliation when methods disagree, multiple-testing and effect-size thresholds, the order of operations (count -> QC -> CN-correct -> hit-call -> validate), the second-best-sgRNA conservative rule, and consensus-hit strategy. Use when choosing among MAGeCK / BAGEL2 / drugZ / JACKS / Chronos for a given design, reconciling disagreement across two or three methods on the same screen, deciding whether to require consensus, gating downstream validation by hit-confidence tier, or interpreting unstable hit lists across reruns.

日本語の概要は準備中です。原文の説明を表示しています。

Build volcano and MA plots from differential-expression / association results with LFC shrinkage, FDR-adjusted thresholds, sensible label placement, and axis-truncation conventions. Covers EnhancedVolcano, ggplot2, matplotlib, and the apeglm/ashr/normal shrinkage decision. Use when visualizing differential-expression results (RNA-seq, ChIP-seq, ATAC-seq, proteomics) or any per-feature effect-size + p-value table.

日本語の概要は準備中です。原文の説明を表示しています。

Analyzes pooled CRISPR screens with MAGeCK (Li et al 2014), covering count generation (mageck count), the RRA two-condition workflow (mageck test using alpha-RRA over per-sgRNA negative-binomial p-values), the MLE multi-condition workflow (mageck mle with explicit design matrix and beta-score output), normalization choice (median vs total vs control-sgRNA vs spike-in), sgRNA efficiency injection, paired-sample testing, time-course design, drug-screen versus dropout-screen design matrices, MAGeCKFlute and MAGeCK-VISPR downstream visualization, and decision logic for when to use MAGeCK vs JACKS / BAGEL2 / drugZ / Chronos. Use when running a fresh CRISPR screen analysis, picking RRA vs MLE for the experimental design, choosing a normalization method from QC signatures, debugging MLE convergence failure or NaN beta scores, comparing MAGeCK output across tools, or building a batch-aware multi-cell-line / multi-condition MLE design matrix.

日本語の概要は準備中です。原文の説明を表示しています。

Query protein-protein and gene interaction databases (STRING, BioGRID, IntAct, SIGNOR, Reactome, HuRI, HuMAP, OmniPath, ConsensusPathDB, DIP). Use when building PPI networks, choosing between physical vs functional vs genetic interactions, signed/directed vs undirected, high-throughput vs curated, picking confidence thresholds, aggregating across resources, or navigating license constraints. Encodes the database decision matrix, STRING v12 channel semantics, OmniPath as meta-database, SIGNOR for signed signaling, and per-resource rate limits.

日本語の概要は準備中です。原文の説明を表示しています。

Prioritizes rare-disease variants from trio/quad WES/WGS with de novo (DeNovoGear, Triodenovo), compound-heterozygous phasing (WhatsHap), mosaic VAF tiering, phenotype-driven ranking (Exomiser, Phen2Gene, AMELIE), ClinGen gene-disease validity gating, and ACMG SF v3.2 secondary findings reporting. Use when running diagnostic exome / genome pipelines, identifying candidate Mendelian disease genes, screening for incidental findings, or auditing VUS reclassification cycles. The ACMG/AMP classification framework (PVS1 decision tree, Pejaver PP3/BP4 calibration, Tavtigian point system) is in clinical-databases/acmg-classification.

日本語の概要は準備中です。原文の説明を表示しています。

Applies ACMG/AMP 2015 framework with ClinGen SVI specifications, Tavtigian 2018/2020 Bayesian point system, Abou Tayoun 2018 PVS1 decision tree, Pejaver 2022 calibrated PP3/BP4 thresholds for REVEL/BayesDel/AlphaMissense, Brnich 2020 PS3/BS3 OddsPath, Walker 2023 SpliceAI splicing framework, and AMP/ASCO/CAP 2017 tumor tiers. Use when classifying germline variants P / LP / VUS / LB / B, applying VCEP-specific CSpec rules, computing Whiffin BS1, or assigning cancer Tier I-IV per Li 2017.

日本語の概要は準備中です。原文の説明を表示しています。

Extracts and assigns COSMIC v3.4 mutational signatures (84 SBS / 11 DBS / 18 ID / 24 CN / 16 SV) from somatic VCFs using SigProfilerSuite, MutationalPatterns, MuSiCal mvNMF, SigNet, or HRDetect. Use when characterizing DNA-damage etiology (BRCA1/2 HRD, MMR-D, POLE, APOBEC3A, UV, tobacco, aflatoxin, 5-FU/SBS17b, platinum, colibactin SBS88), routing PARP inhibitor decisions, or auditing de novo extraction vs refit choice for cohort size.

日本語の概要は準備中です。原文の説明を表示しています。

Generates 3D conformer ensembles using RDKit ETKDGv3 with knowledge-enhanced distance geometry, MMFF94/UFF force-field optimization, CREST + GFN2-xTB semi-empirical refinement, and macrocycle-aware torsion preferences. Provides explicit decision rules for single vs ensemble conformer use, RMSD pruning, energy windows, conformer count, and force-field choice. Use when preparing 3D ligands for docking, generating descriptor input for 3D QSAR, or sampling macrocycle/peptide conformational ensembles.

日本語の概要は準備中です。原文の説明を表示しています。

Analyzes alternative splicing at single-cell resolution. The first decision is library chemistry — 10X 3' is fundamentally limited (RT primes from poly-A, R2 falls in 3' UTR, <0.1 junction read per cell per AS event). Plate-based full-length methods (Smart-seq3, FLASH-seq, VASA-seq, STORM-seq) and single-cell long-read (MAS-Iso-seq, scISOr-Seq2) are the chemistries that give per-cell isoform structure. Tools include MARVEL (R, Smart-seq integrated), BRIE2 (Bayesian PSI with regulatory features and ELBO_gain test), scQuint (junction-cluster, plate-based; not for 10X), SpliZ (annotation-free Z-score), Psix (graph-smoothness regulated AS), and Sierra (alternative polyadenylation, often confused with AS). Use when analyzing isoform usage in scRNA-seq, identifying cell-type-specific splicing, or determining whether scRNA-seq chemistry supports splicing analysis at all.

日本語の概要は準備中です。原文の説明を表示しています。

Multi-agent council for code review and architecture decisions

日本語の概要は準備中です。原文の説明を表示しています。

Combine React's official "You Might Not Need an Effect" guidance with this project's stricter no direct useEffect stance. Use when writing, reviewing, or refactoring React components that might reach for useEffect, derived state, event relays, reset logic, subscriptions, or client fetching.

日本語の概要は準備中です。原文の説明を表示しています。

Grill the user relentlessly about a plan, decision, or idea. Use when the user wants to stress-test their thinking, or uses any 'grill' trigger phrases ("grill me", "grill with docs").

日本語の概要は準備中です。原文の説明を表示しています。

Autonomous agents are AI systems that can independently decompose goals, plan actions, execute tools, and self-correct without constant human guidance. The challenge isn't making them capable - it's making them reliable. Every extra decision multiplies failure probability.

日本語の概要は準備中です。原文の説明を表示しています。

API design principles and decision-making. REST vs GraphQL vs tRPC selection, response formats, versioning, pagination.

日本語の概要は準備中です。原文の説明を表示しています。

Design, audit, and improve analytics tracking systems that produce reliable, decision-ready data.

日本語の概要は準備中です。原文の説明を表示しています。

A hybrid memory system that provides persistent, searchable knowledge management for AI agents (Architecture, Patterns, Decisions).

日本語の概要は準備中です。原文の説明を表示しています。

Interactive Flutter Widget implementation assistant that guides you through widget implementation decisions by asking structured questions about state management, widget type (screen/component), and state sharing. Use this skill when you need help determining the appropriate Flutter widget architecture for your implementation.

日本語の概要は準備中です。原文の説明を表示しています。

Produce a deterministic, read-only evidence map of the repository for SDD Composy (languages, manifests, commands, modules, boundaries, staleness) and publish the context bundle only on request. Use before a PRD or TechSpec, or when the map is stale — 'mapear o repositório', 'atualizar o contexto do código', 'what does this codebase look like for SDD'. Do NOT use for architecture decisions, code review, or repository exploration without an SDD workspace.

日本語の概要は準備中です。原文の説明を表示しています。

Produce an evidence-backed release readiness opinion while keeping the human release decision separate.

日本語の概要は準備中です。原文の説明を表示しています。

Assess release readiness from applicable criteria, all current defects, risks, limitations, and recorded human decisions without approving release.

日本語の概要は準備中です。原文の説明を表示しています。

Use when the user asks about the pwdev-prd audit trail — 'auditoria do prd', 'eventos', 'decisões registradas', 'audit report', 'exportar relatório de auditoria' — querying the shared SQLite database read-only (summary, events, decisions, artifacts, stats, export, query).

日本語の概要は準備中です。原文の説明を表示しています。

Use when the user wants a small, well-bounded change done now without a plan file — a bugfix, config change, rename, doc update or simple refactor touching 1–5 files — 'corrigir rapidinho', 'quick fix no X', 'renomear Y'. Presents a mini-plan, implements after approval, verifies and commits. Do NOT use for more than 5 files, architectural decisions, migrations or new UI flows (use feat-feature / feat-backend / feat-frontend).

日本語の概要は準備中です。原文の説明を表示しています。

Use when the user wants the existing codebase analyzed for planning — 'mapear o código', 'analisar o projeto', 'atualizar o contexto', 'map codebase' — or when a planning skill reports a missing or stale map. Runs a deterministic read-only evidence scan and writes codebase.md plus the architecture, conventions, testing and concerns context documents under .planning/feat/. Do NOT use for code review (feat-review), architecture decisions, or writing the project instructions file (feat-setup).

日本語の概要は準備中です。原文の説明を表示しています。

Design an approval-gated feature specification from approved requirements. Use when PWDEV Flow discovery is complete and the user needs architecture decisions, component boundaries, quality constraints, and a definition of done.

日本語の概要は準備中です。原文の説明を表示しています。